Abstract
CONCLUSION: •Patients with prostate cancer with overexpression of either or both EGFR and HER2 on IHC have an increased risk of biochemical relapse after radical radiotherapy. Alternative strategies of either surgery or utilization of EGFR and HER2 inhibition combined with radiotherapy need to be considered for such patients. :EGFR and HER2 expression was evaluated by immunohistochemistry (IHC) in 84 patients treated with radical radiotherapy in the Northern Centre for Cancer Treatment, in Newcastle in the UK between 1996 and 2000.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
